EA200700876A1 - AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 - Google Patents

AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2

Info

Publication number
EA200700876A1
EA200700876A1 EA200700876A EA200700876A EA200700876A1 EA 200700876 A1 EA200700876 A1 EA 200700876A1 EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A1 EA200700876 A1 EA 200700876A1
Authority
EA
Eurasian Patent Office
Prior art keywords
angiopoetin
specifically binding
agents specifically
antibodies
fragments
Prior art date
Application number
EA200700876A
Other languages
Russian (ru)
Other versions
EA011866B1 (en
Inventor
Джонатон Даниел Олайнер
Кевин Грэхэм
Original Assignee
Амджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Амджен Инк. filed Critical Амджен Инк.
Publication of EA200700876A1 publication Critical patent/EA200700876A1/en
Publication of EA011866B1 publication Critical patent/EA011866B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты специфические связывающие агенты, такие как полностью человеческие антитела, которые связывают ангиопоэтин-2. Раскрыты также фрагменты тяжёлых цепей, фрагменты лёгких цепей и участки, определяющие комплементарность (CDR), в составе антител, а также способы получения и применения этих антител.Specific binding agents are disclosed, such as fully human antibodies that bind angiopoietin-2. Also disclosed are fragments of heavy chains, fragments of light chains, and regions that determine complementarity (CDR) in the composition of antibodies, as well as methods for producing and using these antibodies.

EA200700876A 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents EA011866B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
EA200700876A1 true EA200700876A1 (en) 2007-10-26
EA011866B1 EA011866B1 (en) 2009-06-30

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700876A EA011866B1 (en) 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (en)
CN (1) CN101495513B (en)
BR (1) BRPI0518209A (en)
EA (1) EA011866B1 (en)
IL (1) IL182279A0 (en)
MA (1) MA29015B1 (en)
MX (1) MX2007004247A (en)
RU (2) RU2404992C2 (en)
SG (1) SG156668A1 (en)
ZA (1) ZA200704020B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520188A (en) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド Angiopoietin-2 specific binding substance
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
EP3210625B1 (en) * 2011-09-30 2019-08-28 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
KR102512940B1 (en) 2014-08-28 2023-03-23 에자이 알앤드디 매니지먼트 가부시키가이샤 High-purity quinoline derivative and method for manufacturing same
JP6792546B2 (en) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to suppress bitterness of quinoline derivatives
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN106075448A (en) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation
CN106512006A (en) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas
CN109096368B (en) * 2018-09-30 2021-07-20 华南理工大学 Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof
JP7177284B2 (en) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド Anti-ANG2 antibody and use thereof
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60003011T2 (en) * 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. MODULATING VASCER PERMABILITY BY TIE2 RECEPTOR ACTIVATORS
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003030883A1 (en) * 2001-10-12 2003-04-17 Kosmos Pharma Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
JP2008520188A (en) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド Angiopoietin-2 specific binding substance

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Also Published As

Publication number Publication date
IL182279A0 (en) 2007-07-24
JP2008520188A (en) 2008-06-19
SG156668A1 (en) 2009-11-26
BRPI0518209A (en) 2008-11-04
CN101495513B (en) 2014-08-06
EA011866B1 (en) 2009-06-30
JP2011207882A (en) 2011-10-20
MX2007004247A (en) 2007-06-12
MA29015B1 (en) 2007-11-01
RU2010132956A (en) 2012-02-10
ZA200704020B (en) 2008-06-25
RU2404992C2 (en) 2010-11-27
RU2007118670A (en) 2008-12-27
CN101495513A (en) 2009-07-29

Similar Documents

Publication Publication Date Title
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
RS28904A (en) Angiopoietin-2 specific binding agents
EA200400526A1 (en) AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2
EA201001335A1 (en) ANTIBODIES DIRECTED AGAINST ANGIOPOETHINA-1 AND ANGIOPOETINA-2 AND THEIR APPLICATION
EA201070888A1 (en) ANTIBODIES AND THEIR DERIVATIVES
NO2017032I1 (en) bezlotoksumab
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA200800812A1 (en) Antibody Anti-CD3 Compositions
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
EP1912674B8 (en) Bispecific single chain fv antibody molecules and methods of use thereof
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
TW200617025A (en) Il-17 antagonistic antibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
TW200635946A (en) Binding proteins specific for human matriptase
EA200801172A1 (en) LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006058890A3 (en) Method of producing antibodies

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU